Cargando…

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

SIMPLE SUMMARY: Peptide receptor radionuclide therapy (PRRT) is a systemic treatment consisting of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmadi Bidakhvidi, Niloefar, Goffin, Karolien, Dekervel, Jeroen, Baete, Kristof, Nackaerts, Kristiaan, Clement, Paul, Van Cutsem, Eric, Verslype, Chris, Deroose, Christophe M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749814/ https://www.ncbi.nlm.nih.gov/pubmed/35008293 http://dx.doi.org/10.3390/cancers14010129

Ejemplares similares

Intra-individual qualitative and quantitative comparison of [(68)Ga]Ga-DOTATATE PET/CT and PET/MRI
por: Lens, Géraldine, et al.
Publicado: (2023)

Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumor and liver perfusion territory definition
por: Jafargholi Rangraz, Esmaeel, et al.
Publicado: (2020)

Value of [(68)Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature
por: Deleu, Anne-Leen, et al.
Publicado: (2022)

Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report
por: Haemels, Maarten, et al.
Publicado: (2020)

Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

Somatostatin Receptor Based Imaging and Radionuclide Therapy
por: Xu, Caiyun, et al.
Publicado: (2015)

Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
por: Boeckxstaens, Lennert, et al.
Publicado: (2023)

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
por: Feijtel, Danny, et al.
Publicado: (2021)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016)

Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response
por: Dekervel, Jeroen, et al.
Publicado: (2016)

Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts
por: Bulle, Ashenafi, et al.
Publicado: (2020)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models
por: Ullrich, Martin, et al.
Publicado: (2023)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2017)

Segmentation-guided multi-modal registration of liver images for dose estimation in SIRT
por: Tang, Xikai, et al.
Publicado: (2022)

An uncommon histopathological diagnosis
por: Bode, Hannelore, et al.
Publicado: (2018)

Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up
por: Duan, Heying, et al.
Publicado: (2022)

On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
por: De Coster, Liesbeth, et al.
Publicado: (2018)

How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation
por: Ambrosini, Valentina, et al.
Publicado: (2023)

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
por: Jahn, Ulrika, et al.
Publicado: (2023)

Somatostatin Decorated Quantum Dots for Targeting of Somatostatin Receptors
por: Hafez Abdellatif, Ahmed Abdelfattah, et al.
Publicado: (2018)

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
por: Shamsi, Bilal Haider, et al.
Publicado: (2021)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma
por: Harda, Kristof, et al.
Publicado: (2018)

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study
por: Ebbers, Sander C., et al.
Publicado: (2021)

Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
por: Hall, G H, et al.
Publicado: (2002)

Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4
por: Börzsei, Rita, et al.
Publicado: (2022)

Somatostatin receptor scintigraphy in sarcoidosis
por: Kamphuis, Lieke SJ, et al.
Publicado: (2011)

Comment on: Somatostatin receptor SPECT
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2012)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
por: Brackenier, Cedric, et al.
Publicado: (2023)

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE
por: Delbart, Wendy, et al.
Publicado: (2023)

Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer
por: SHI, XUEFEI, et al.
Publicado: (2013)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization
por: Jafargholi Rangraz, Esmaeel, et al.
Publicado: (2019)

Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
por: Cullinane, Carleen, et al.
Publicado: (2020)

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
por: Günther, Thomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g0ha5ml74ttuld6a1gmj75jtr3